Literature DB >> 29761863

Surgical treatment of esophageal cancer in the era of multimodality management.

Alicia S Borggreve1,2, B Feike Kingma1, Serg A Domrachev3, Mikhail A Koshkin2, Jelle P Ruurda1, Richard van Hillegersberg1, Flavio R Takeda4, Lucas Goense1.   

Abstract

Over the last decades, the treatment of resectable esophageal cancer has evolved into a multidisciplinary process in which all players are essential for treatment to be successful. Medical oncologists and radiation oncologists have been increasingly involved since the implementation of neoadjuvant therapy, which has been shown to improve survival. Although esophagectomy is still considered the cornerstone of curative treatment for locally advanced esophageal cancer, it remains associated with considerable postoperative morbidity, despite promising results of minimally invasive techniques. In this light, both physical status and response to neoadjuvant therapy may be important factors for selecting patients who will benefit from surgery. Furthermore, it is important to optimize the entire perioperative trajectory: from the initial outpatient clinic visit to postoperative discharge. Enhanced recovery after surgery is increasingly recognized for esophagectomy and emphasizes perioperative aspects, such as nutrition, physiotherapy, and pain management. To date, several facets of esophageal cancer treatment remain topics of debate, such as the preferred neoadjuvant treatment, anastomotic technique, extent of lymphadenectomy, organization of postoperative care, and the role of surgery beyond locally advanced disease. Here, we describe the current and future perspectives in the surgical treatment of patients with esophageal cancer in the context of the available literature.
© 2018 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals, Inc. on behalf of The New York Academy of Sciences.

Entities:  

Keywords:  enhanced recovery; esophageal cancer; esophageal surgery; patient selection; perioperative treatment

Mesh:

Year:  2018        PMID: 29761863     DOI: 10.1111/nyas.13677

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  24 in total

1.  Tumor size predicts worse prognosis in esophagogastric junction adenocarcinoma.

Authors:  Flavio Roberto Takeda; Marcus Fernando Kodama Pertille Ramos; Marina Alessandra Pereira; Rubens Antonio Aissar Sallum; Ulysses Ribeiro Junior; Sergio Carlos Nahas; Ivan Cecconello
Journal:  Updates Surg       Date:  2022-07-01

2.  Construction and evaluation of prognostic models for esophageal cancer patients with distant and non-distant metastases: providing a reference process for clinical diagnosis and treatment.

Authors:  Mingxin Zhang; Manli Cui; Qianqian Zuo; Li Wang; Jia Wang; Lin Zhu; Rong Yan; Ning Lu; Honglin Yan; Lingmin Zhang
Journal:  J Gastrointest Oncol       Date:  2021-08

3.  Patients with Isolated Brain Metastases from Esophageal Carcinoma After Minimally Invasive Esophagectomy May Not Have a Dismal Prognosis.

Authors:  Sanne K Stuart; Toon J L Kuypers; Ingrid S Martijnse; Joos Heisterkamp; Robert A Matthijsen
Journal:  J Gastrointest Cancer       Date:  2022-10-03

4.  Effects of standard and total two-field lymph node dissection on prognosis of patients undergoing Esophagectomy.

Authors:  Qiang Guo; Hefei Li; Haibo Wang; Duo Zhang; Yonghui Li
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 2.340

5.  Circ_0006948 Contributes to Cell Growth, Migration, Invasion and Epithelial-Mesenchymal Transition in Esophageal Carcinoma.

Authors:  Meng Yue; Yanxia Liu; Taiyang Zuo; Yakun Jiang; Jianmei Pan; Shuhong Zhang; Xingjie Shen
Journal:  Dig Dis Sci       Date:  2021-02-25       Impact factor: 3.199

Review 6.  Molecular mechanisms associated with chemoresistance in esophageal cancer.

Authors:  Matheus Lohan-Codeço; Maria Luísa Barambo-Wagner; Luiz Eurico Nasciutti; Luis Felipe Ribeiro Pinto; Nathalia Meireles Da Costa; Antonio Palumbo
Journal:  Cell Mol Life Sci       Date:  2022-02-03       Impact factor: 9.261

7.  Prognostic evaluation of esophageal cancer patients with stages I-III.

Authors:  Meng-Jun Qiu; Sheng-Li Yang; Meng-Meng Wang; Ya-Nan Li; Xin Jiang; Zao-Zao Huang; Zhi-Fan Xiong
Journal:  Aging (Albany NY)       Date:  2020-07-23       Impact factor: 5.682

8.  Cloperastine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by suppressing mitochondrial oxidative phosphorylation.

Authors:  Bo Li; Yin Yu; Yanan Jiang; Lili Zhao; Ang Li; Mingzhu Li; Baoyin Yuan; Jing Lu; Ziming Dong; Jimin Zhao; Kangdong Liu
Journal:  Cell Death Discov       Date:  2021-06-21

9.  Post-esophagectomy Symptomatic Dunbar Syndrome: A rare diagnosis of abdominal pain after surgery.

Authors:  Flavio Roberto Takeda; George Felipe Bezerra Darce; Lucas Faraco Sobrado; Luisa Leitão de Faria; Francisco Tustumi; Rubens Antonio Aissar Sallum; Manoel de Souza Rocha; Ulysses Ribeiro; Ivan Cecconello
Journal:  Int J Surg Case Rep       Date:  2020-03-07

10.  High expression of CIN85 promotes proliferation and invasion of human esophageal squamous cell carcinoma.

Authors:  Xiao-Yang Hua; Xing-Xing Bie; Xi Cheng; Shu-Guang Zhang
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.